New Haven, CT Clinical Trials Report — May 2026

For New Haven residents considering participation in clinical research, May 2026 offers important opportunities, particularly with several trials nearing their enrollment deadlines. Across New Haven, 831 clinical trials are currently recruiting across 264 research facilities, providing numerous avenues to contribute to medical advancements.

A total of 48 clinical trials are scheduled to close within the next 90 days. This urgency is especially relevant for healthy volunteers, as 8 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also have limited time to join research. Trials focused on various cancers, substance use disorders, and metabolic conditions are among those with impending deadlines. Conditions with trials closing soon include:

• Advanced solid tumor (3 trials)
• Triple negative breast cancer (2 trials)
• Stage iv lung cancer ajcc v8 (2 trials)
• Alcohol use disorder (aud) (2 trials)
• Type 2 diabetes (2 trials)
• Advanced malignant solid neoplasm (1 trial)
• Advanced malignant neoplasm (1 trial)
• Acute ischemic stroke (1 trial)
• Alcohol use (1 trial)

New Research Opportunities Emerge

This month, New Haven saw the opening of 12 new clinical trials, a slight decrease from the 13 trials that launched in April 2026. This consistent activity underscores New Haven's robust research landscape.

May brings several notable new trials to New Haven, including studies from major sponsors and academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges. Of the new trials, 7 are drug trials, 6 are categorized as "other" types, 1 is behavioral, and 1 is a device trial. Industry sponsors account for 7 of these new trials, while academic or other sponsors account for 5.

• The Duchenne Registry is sponsoring NCT07609394, "Duchenne Electronic Health Record Study." This study aims to collect long-term data from 2,500 participants with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic health record transfer.
• Mother's Milk is Best is behind NCT07576972, "Human Milk Concentrating Device to Optimize Mother's Own Milk." This randomized trial with 310 participants evaluates a human milk concentration device for preterm infants.
• Yale University is sponsoring NCT07602218, "Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 2." This study, involving 300 participants, refines a clinical decision support system to improve buprenorphine administration for opioid use disorder.
• The University of Southern California is leading NCT07602699, "Multi-Site Trial of Tirzepatide for Smoking Cessation." This Phase 2 trial with 300 participants will generate data on the efficacy of tirzepatide for smoking cessation in people who smoke with overweight or obesity.
• Also from Yale University, NCT07610369, "The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease," is a Phase 2 study with 40 participants. It aims to understand if psilocybin therapy can improve depression symptoms in individuals with Parkinson's Disease.

New trials this month are exploring a range of conditions, with the most frequent being healthy volunteer studies (3 trials), followed by Alzheimer disease (1 trial), Becker muscular dystrophy (1 trial), and depression (1 trial). Major sponsors like Pfizer (4 new trials), Yale University (3 new trials), and Novo Nordisk A/S (1 new trial) are driving significant research efforts in New Haven.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 12 new trials launched this month, 4 are actively seeking healthy volunteers. Across New Haven, a total of 99 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

New Haven's Leading Research Facilities

New Haven is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Yale University (255 trials)
• Yale Cancer Center (74 trials)
• Yale New Haven Hospital (56 trials)
• Yale University School of Medicine (53 trials)
• Yale School of Medicine (36 trials)
• Smilow Cancer Center/Yale-New Haven Hospital (24 trials)
• Research Site (17 trials)
• Yale-New Haven Hospital (14 trials)
• Yale University, Yale Cancer Center (11 trials)
• Connecticut Mental Health Center (9 trials)

These institutions, particularly Yale University and its affiliated medical centers, offer a broad spectrum of research, from oncology at Yale Cancer Center and Smilow Cancer Center to diverse medical fields across the university and hospital systems.

Broadening Your Search: Nearby Options

While New Haven offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Connecticut. Cities with active trials include Stamford (2 trials), Glastonbury (1 trial), Guilford (1 trial), Storrs (1 trial), Waterford (1 trial), and Westport (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 12 new trials launched this month, 9 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, with no new trials specifically for female-only or male-only participants this month.

As we move further into spring, New Haven's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.